The US Food and Drug Administration (FDA) has granted Nacuity Pharmaceuticals’ N-acetylcysteine amide tablets (NPI-001) a ...
Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by oxidative stress, today announced that ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to NPI-001 (N-acetylcysteine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback